source
- Eli Lilly commits $100M upfront in new five-target partnership with China's InnoCareEli Lilly has agreed to pay $100 million upfront and in the near term to Chinese biotech InnoCare Pharma as part of a five‑target drug discovery partnership. The agreement also provides for up to $…
- Merck's remigromig meets visual acuity goal in diabetic macular edema trial, safety signals notedMerck announced that its experimental eye drug remigromig achieved non‑inferiority to Roche’s Lucentis in a late‑stage trial for diabetic macular edema. The trial, called Brunello, measured visual…